Search BIO-B
BIO-RAD LABORATORIES, INC.
NYSE, NYSE · CIK 12208
Last close365.08
Daily change+0.00 (0.00%)
10 Years gain+124.64%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
BIO-B · STANDARD
SIC 3826 · Laboratory Analytical Instruments · Fiscal year end 1231
Fundamental
37.1Momentum
51.7Acceleration
52.0Confidence
91.0Annual Revenue18
Quarterly Revenue73
Annual CFO18
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth3.1 / 25
Quality7.8 / 25
Capital Efficiency4.2 / 20
Balance Sheet10.8 / 15
Shareholder Economics9.6 / 10
Forward Indicators1.5 / 5
Signals
Operating leverageOperating margin improved by 0.3466 percentage points.
ROIC expansionROIC improved by 0.4564 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 4.0816%.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Key Metrics
Revenue Growth TTM2.55%OK
Revenue CAGR 3Y-2.68%OK
Gross Margin52.75%OK
Operating Margin9.78%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC2.92%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-4.08%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $2.58B | $1.34B | $47.20M | $532.20M | $374.60M | 51.87% | 1.83% | 14.5% | 0.55% | 27.28M |
| 2025 FY Dec 31, 2024 | $2.57B | $1.38B | $269.00M | $455.20M | $289.60M | 53.73% | 10.48% | 11.28% | 2.94% | 28.21M |
| 2025 FY Dec 31, 2023 | $2.67B | $1.43B | $337.80M | $374.90M | $218.20M | 53.42% | 12.65% | 8.17% | 3.07% | 29.21M |
| 2024 FY Dec 31, 2022 | $2.80B | $1.57B | $482.60M | $194.40M | $81.60M | 55.93% | 17.22% | 2.91% | 3.49% | 29.79M |
| 2023 FY Dec 31, 2021 | $2.92B | $1.64B | $500.34M | $669.46M | $535.72M | 56.05% | 17.12% | 18.33% | 3.6% | 30.21M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $2.55B | sum latest 4 fiscal quarters Revenue | OK | 0000012208-26-000048, 0000012208-25-000077 |
| Revenue Growth TTM | 2.55% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000012208-26-000048, 0000012208-25-000077 |
| Revenue CAGR 3Y | -2.68% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0000012208-26-000010 |
| Revenue CAGR 5Y | 0.29% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0000012208-26-000010 |
| Gross Profit CAGR 3Y | -5.09% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0000012208-26-000010 |
| Operating Income Growth | 6.32% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0000012208-26-000048, 0000012208-25-000077 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 52.75% | Gross Profit / Revenue | OK | 0000012208-26-000048, 0000012208-25-000077 |
| Operating Margin | 9.78% | Operating Income / Revenue | OK | 0000012208-26-000048, 0000012208-25-000077 |
| ROIC | 2.92% | NOPAT / Average Invested Capital | OK | 0000012208-26-000048, 0000012208-25-000077 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0000012208-26-000048 |
| Interest Coverage | 5.05x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 3.14x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 1.34x | (Cash + Short-term Investments) / Total Debt | OK | 0000012208-26-000048 |